As PI3Kβ is an effector of multiple tyrosine kinase activities that can mediate ALK inhibitor resistance, including EGFR, the co‐targeting of PI3Kβ and ALK offers promise as a treatment for ALK‐rearranged lung cancer. Here, EGFR is linked to lung carcinoma.